\babel@toc {english}{}
\contentsline {chapter}{\numberline {1}Transcription}{3}{chapter.1}% 
\contentsline {section}{\numberline {1.1}Recap on transcription}{3}{section.1.1}% 
\contentsline {section}{\numberline {1.2}2- Transcriptional Control in Cancer}{3}{section.1.2}% 
\contentsline {subsection}{\numberline {1.2.1}Transcription initiation}{3}{subsection.1.2.1}% 
\contentsline {subsection}{\numberline {1.2.2}Chromatin remodeling}{5}{subsection.1.2.2}% 
\contentsline {subsubsection}{\numberline {1.2.2.1}Techniques to study chromatin remodelling}{5}{subsubsection.1.2.2.1}% 
\contentsline {subsection}{\numberline {1.2.3}Nucleosome organization}{6}{subsection.1.2.3}% 
\contentsline {subsubsection}{\numberline {1.2.3.1}Nucleosome remodelling}{6}{subsubsection.1.2.3.1}% 
\contentsline {section}{\numberline {1.3}3 (1)}{7}{section.1.3}% 
\contentsline {subsection}{\numberline {1.3.1}Main nucleosome modifications in promoters:}{8}{subsection.1.3.1}% 
\contentsline {subsubsection}{\numberline {1.3.1.1}RT-qPCR based detection of 5' RNA transcripts of inactive genes}{8}{subsubsection.1.3.1.1}% 
\contentsline {subsubsection}{\numberline {1.3.1.2}Global run-on sequencing (GRO-seq)}{9}{subsubsection.1.3.1.2}% 
\contentsline {subsubsection}{\numberline {1.3.1.3}Transcription pausing mechanism}{11}{subsubsection.1.3.1.3}% 
\contentsline {section}{\numberline {1.4}4 - TCiC (1)}{12}{section.1.4}% 
\contentsline {subsection}{\numberline {1.4.1}Structural basis of the nucleosome transition during RNA pol II passage - Kujirai et al 2018}{12}{subsection.1.4.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.1}Nucleosome structure}{12}{subsubsection.1.4.1.1}% 
\contentsline {subsubsection}{\numberline {1.4.1.2}Cryo-EM}{12}{subsubsection.1.4.1.2}% 
\contentsline {subsubsection}{\numberline {1.4.1.3}Summary of the main results}{14}{subsubsection.1.4.1.3}% 
\contentsline {subsubsection}{\numberline {1.4.1.4}Template looping}{14}{subsubsection.1.4.1.4}% 
\contentsline {subsubsection}{\numberline {1.4.1.5}Structural basis of nucleosome disassembly and reassembly by RNA P II elongation complex with FACT - Ehara et al.}{15}{subsubsection.1.4.1.5}% 
\contentsline {section}{\numberline {1.5}Termination}{16}{section.1.5}% 
\contentsline {subsubsection}{\numberline {1.5.0.1}Promoter reporter assay}{16}{subsubsection.1.5.0.1}% 
\contentsline {subsubsection}{\numberline {1.5.0.2}\textbf {Promoter types}}{17}{subsubsection.1.5.0.2}% 
\contentsline {subsubsection}{\numberline {1.5.0.3}Transcription factor binding}{18}{subsubsection.1.5.0.3}% 
\contentsline {chapter}{\numberline {2}Enhancer regulation}{20}{chapter.2}% 
\contentsline {section}{\numberline {2.1}5 - TCiC (1)}{20}{section.2.1}% 
\contentsline {subsubsection}{\numberline {2.1.0.1}Mediator complex}{20}{subsubsection.2.1.0.1}% 
\contentsline {subsection}{\numberline {2.1.1}Wnt signalling pathway}{22}{subsection.2.1.1}% 
\contentsline {subsubsection}{\numberline {2.1.1.1}$\beta $ -catenin structure}{23}{subsubsection.2.1.1.1}% 
\contentsline {subsubsection}{\numberline {2.1.1.2}\textbf {The canonical Wnt/$\beta $ -catenin pathway is crucially involved in colorectal cancer}}{24}{subsubsection.2.1.1.2}% 
\contentsline {section}{\numberline {2.2}6- Transcriptional Control in Cancer}{26}{section.2.2}% 
\contentsline {section}{\numberline {2.3}CREP/p300}{26}{section.2.3}% 
\contentsline {subsubsection}{\numberline {2.3.0.1}CREP/p300 structure}{26}{subsubsection.2.3.0.1}% 
\contentsline {subsection}{\numberline {2.3.1}\textbf {TSSa-RNAs transcription}}{28}{subsection.2.3.1}% 
\contentsline {subsubsection}{\numberline {2.3.1.1}Properties of eRNAs}{29}{subsubsection.2.3.1.1}% 
\contentsline {subsubsection}{\numberline {2.3.1.2}\textbf {Assessing whether the CRC 8q24 risk region acts as an enhancer}}{30}{subsubsection.2.3.1.2}% 
\contentsline {chapter}{\numberline {3}CTCF}{32}{chapter.3}% 
\contentsline {section}{\numberline {3.1}7- Transcriptional Control in Cancer}{32}{section.3.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.1}Cohesin mediates transcriptional insulation by CCCTC-binding factor}{36}{subsubsection.3.1.0.1}% 
\contentsline {subsubsection}{\numberline {3.1.0.2}Chromosome Conformation Capture (3C)}{39}{subsubsection.3.1.0.2}% 
\contentsline {subsubsection}{\numberline {3.1.0.3}Hi-C approach}{39}{subsubsection.3.1.0.3}% 
\contentsline {subsubsection}{\numberline {3.1.0.4}Optimization of Hi-C approach}{41}{subsubsection.3.1.0.4}% 
\contentsline {subsubsection}{\numberline {3.1.0.5}Promoter-Enhancer Communication Occurs Primarily within Insulated neighbourhoods}{44}{subsubsection.3.1.0.5}% 
\contentsline {chapter}{\numberline {4}TCIC}{46}{chapter.4}% 
\contentsline {section}{\numberline {4.1}13- Transcriptional Control in Cancer}{46}{section.4.1}% 
\contentsline {section}{\numberline {4.2}Targeting transcription in cancer}{46}{section.4.2}% 
\contentsline {subsubsection}{\numberline {4.2.0.1}Age-related remodellling of \textbf {oesophageal epithelia by mutated cancer drivers}}{46}{subsubsection.4.2.0.1}% 
\contentsline {subsubsection}{\numberline {4.2.0.2}Key points}{49}{subsubsection.4.2.0.2}% 
\contentsline {subsection}{\numberline {4.2.1}Target transcription in cancer}{51}{subsection.4.2.1}% 
\contentsline {section}{\numberline {4.3}15- Transcriptional Control in Cancer}{52}{section.4.3}% 
\contentsline {section}{\numberline {4.4}BRD4}{52}{section.4.4}% 
\contentsline {subsubsection}{\numberline {4.4.0.1}Selective inhibition of Tumor Oncogenes by Disruption of Super-Enhancers}{52}{subsubsection.4.4.0.1}% 
\contentsline {section}{\numberline {4.5}YAP/TAZ}{53}{section.4.5}% 
\contentsline {section}{\numberline {4.6}TEAD}{55}{section.4.6}% 
\contentsline {subsection}{\numberline {4.6.1}YAP/TAZ/TEAD}{55}{subsection.4.6.1}% 
\contentsline {section}{\numberline {4.7}17- Transcriptional Control in Cancer}{56}{section.4.7}% 
\contentsline {section}{\numberline {4.8}Nuclear receptors}{56}{section.4.8}% 
\contentsline {subsection}{\numberline {4.8.1}Estrogen receptor \(\alpha \)}{57}{subsection.4.8.1}% 
\contentsline {subsection}{\numberline {4.8.2}ER$\alpha $) in breast cancer}{57}{subsection.4.8.2}% 
\contentsline {subsubsection}{\numberline {4.8.2.1}Mechanisms provoking breast cancer drug resistance}{59}{subsubsection.4.8.2.1}% 
\contentsline {subsubsection}{\numberline {4.8.2.2}Summary}{59}{subsubsection.4.8.2.2}% 
\contentsline {subsubsection}{\numberline {4.8.2.3}ER$\alpha $ transcriptional program}{60}{subsubsection.4.8.2.3}% 
\contentsline {chapter}{\numberline {5}Genome instability}{62}{chapter.5}% 
\contentsline {section}{\numberline {5.1}19- Transcriptional Control in Cancer}{62}{section.5.1}% 
\contentsline {section}{\numberline {5.2}Transcription and genome instability}{62}{section.5.2}% 
\contentsline {subsection}{\numberline {5.2.1}R-loops}{62}{subsection.5.2.1}% 
\contentsline {subsubsection}{\numberline {5.2.1.1}R-loop degradation}{63}{subsubsection.5.2.1.1}% 
\contentsline {subsubsection}{\numberline {5.2.1.2}R-loop recognition and distribution}{63}{subsubsection.5.2.1.2}% 
\contentsline {subsubsection}{\numberline {5.2.1.3}VIM-antisense1}{64}{subsubsection.5.2.1.3}% 
\contentsline {subsubsection}{\numberline {5.2.1.4}Main findings}{65}{subsubsection.5.2.1.4}% 
\contentsline {subsection}{\numberline {5.2.2}HOTTIP-dependent R-loop formation regulates CTCF boundary activity and TAD integrity in leukemia}{65}{subsection.5.2.2}% 
\contentsline {subsubsection}{\numberline {5.2.2.1}Conclusions}{67}{subsubsection.5.2.2.1}% 
\contentsline {subsection}{\numberline {5.2.3}HOTTIP lncRNA Promotes Hematopoietic Stem Cells Self-Renewal Leading to AML-like Disease in Mice}{67}{subsection.5.2.3}% 
\contentsline {section}{\numberline {5.3}20- Transcriptional Control in Cancer}{67}{section.5.3}% 
\contentsline {section}{\numberline {5.4}Transcription and genome instability II}{67}{section.5.4}% 
\contentsline {subsection}{\numberline {5.4.1}DNA damage}{67}{subsection.5.4.1}% 
\contentsline {subsubsection}{\numberline {5.4.1.1}R loop modified bases}{68}{subsubsection.5.4.1.1}% 
\contentsline {subsection}{\numberline {5.4.2}Apical kinases}{68}{subsection.5.4.2}% 
\contentsline {subsection}{\numberline {5.4.3}Topoisomerases}{71}{subsection.5.4.3}% 
\contentsline {subsubsection}{\numberline {5.4.3.1}A topoisomerase IIb-mediated dsDNA break required for Regulated Transcription}{71}{subsubsection.5.4.3.1}% 
\contentsline {subsubsection}{\numberline {5.4.3.2}BRCA1}{72}{subsubsection.5.4.3.2}% 
\contentsline {subsubsection}{\numberline {5.4.3.3}Stark et al.}{72}{subsubsection.5.4.3.3}% 
